Drugs, Supplies and Delivery
Tirzepatide, marketed as Mounjaro®, is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Approved for type 2 diabetes mellitus (T2DM), it offers superior glycemic control and weight loss compared to traditional GLP-1 agonists. This article synthesizes evidence from the British National Formulary (BNF), Lippincott Textbook of Pharmacology, and Lange Basic & Clinical Pharmacology to detail its pharmacology, clinical use, and safety profile.
Tirzepatide’s unique dual agonism targets two incretin pathways:
The synergistic action improves both fasting and postprandial glucose while promoting significant weight loss (up to 15% in clinical trials) (Lange).
Ongoing trials (e.g., SURPASS-CVOT) investigate MACE reduction
Serious:
Hypersensitivity to tirzepatide
Category C; avoid during pregnancy/breastfeeding (BNF).
We provide fast and secure prescription reservations—place your order now and pick it up from the nearest pharmacy!
© 2025 Created with Za-Pharmacy
© 2025 تم إنشاؤها بالتعاون مع صحتك في خمسة